pipeline | autoimmune/inflammation | oncology
ALPN-101 is targeted to begin clinical studies in Q1-2019. ALPN-202 is targeted to enter the clinic in Q4-2019
Our lead program, ALPN-101, demonstrated preclinical activity in inflammatory arthritis and multiple sclerosis mode… twitter.com/i/web/status/10543…
October 22, 2018 2:00 pm
We’re planning to bring ALPN-101, our dual ICOS/CD28 antagonist, to #arthritis patients. We will present preclinica… twitter.com/i/web/status/10507…
October 12, 2018 4:02 pm
© 2018 Alpine Immune Sciences. All Rights Reserved, Alpine Immune Sciences Inc.